British Patient Capital has committed £25 million to the second Dementia Discovery Fund, aiming to enhance the development of innovative therapeutics for dementia while fostering the UK’s position in the life sciences sector.

Target Information

British Patient Capital, a commercial subsidiary of the British Business Bank, has committed £25 million to the Dementia Discovery Fund 2 (DDF-2), which is managed by SV Health Investors. This investment follows British Patient Capital’s previous commitment of £24 million to the first Dementia Discovery Fund. The Dementia Discovery Fund focuses exclusively on financing companies that develop innovative therapeutics for dementia, which remains one of the most significant global medical and societal challenges, currently affecting 55 million individuals worldwide.

Since its inception in 2015, the DDF has built a robust portfolio comprising 19 promising companies. This portfolio has produced 11 assets currently in clinical trials, significant follow-on investments, and numerous strategic partnerships with pharmaceutical firms. With the recent commitment from British Patient Capital, DDF-2 has successfully reached its target of raising $250 million.

Industry Overview

The landscape of neurodegenerative disease research has seen transformative advancements over the past decade, significantly enhancing our comprehension of the factors contributing t